Anxiolytic effects of the novel anti-epileptic drug levetiracetam in the elevated plus-maze test in the rat

European Journal of Pharmacology

Volumn 481, Issue 1, 2003, Pages 67-74

  Gower, Alma J ^a   Falter, Ursula ^a   Lamberty, Yves ^a  

^a UCB PHARMA   (Belgium)

Author keywords

Anti epileptic; Anxiety; Buspirone; Chlordiazepoxide; Levetiracetam; Plus maze test

Indexed keywords

ANTICONVULSIVE AGENT; ANXIOLYTIC AGENT; BUSPIRONE; CHLORDIAZEPOXIDE; ETIRACETAM;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY DISORDER; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EXPOSURE; DRUG SCREENING; MALE; MAZE TEST; NONHUMAN; PRIORITY JOURNAL; RAT; TRANQUILIZING ACTIVITY;

EID: 0345016418     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2003.09.004     Document Type: Article

References (48)

1. Argyropoulos S.V., Sandford J.J., Nutt D.J. The psychobiology of anxiolytic drugs: part 2. Pharmacological treatments of anxiety. Pharmacol. Ther. 88:2000;213-227.
2. Bandelow B., Zohar J., Hollander E., Kasper S., Moller H.-J. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders. World J. Biol. Psych. 2:2002;171-199.
3. Bertaglio L.J., Carobrez A.P. Previous experience required to increase open arms avoidance in rats submitted to the elevated plus-maze model of anxiety. Behav. Brain Res. 108:2000;197-203.
4. Cramer J.A., Arrigio C., Van Hammer H., Bromfield E.B. Comparison between the QOLIE-31 and derived QOLIE-10 in a clinical trial of levetiracetam. Epilepsy Res. 41:2000;29-38.
5. 2 receptors. Psychopharmacology. 93:1987;502-506.
6. Dal-Cól M.L.C., Orlandi Pereira L., Rosa V.P., Calixto A.V., Carobrez A.P., Faria M.S. Lack of midazelam-induced anxiolysis in the plus-maze Trial 2 is dependent on the length of Trial 1. Pharmacol. Biochem. Behav. 74:2003;395-400.
7. Dalvi A., Rodgers R.J. Anxiolytic effect of valproate and diazepam in mice are differentially sensitive to picrotoxin antagonism. Pharmacol. Biochem. Behav. 68:2001;23-32.
8. Dawson G.R., Tricklebank M.D. Use of the elevated plus maze in the search for novel anxiolytic agents. Trends Pharmacol. Sci. 16:1995;33-36.
9. Dooley M., Plosker G.L. Levetiracetam: a review of its adjunctive use in the management of partial onset seizures. Drugs. 60(4):2000;871-893.
10. 1A receptor agonists and NMDA receptor antagonists in the social interaction test and the elevated plus-maze. Eur. J. Pharmacol. 169:1989;1-10.
11. Falter U., Gower A.J., Gobert J. Resistance of baseline activity in the elevated plus-maze to exogenous influences. Behav. Pharmacol. 3:1992;123-128.
12. File S.E., Zangrossi H. "One-trial tolerance" to the anxiolytic actions of benzodiazepines in the elevated plus-maze, or the development of a phobic state? Psychopharmacology. 110:1993;240-244.
13. File S.E., Andrews N., Wu P.Y., Zharkovsky A., Zangrossi H. Jr. Modification of chlordiazepoxide's behavioural and neurochemical effects by handling and plus-maze experience. Eur. J. Pharmacol. 218:1992;9-14.
14. File S.E., Zangrossi H. Jr., Viana M., Graeff F.G. Trial 2 in the elevated plus-maze: a different form of fear? Psychopharmacology. 111:1993;491-494.
15. Gelenberg A.J. Psychiatric and somatic markers of anxiety: identification and pharmacologic treatment. Prim. Care Companion J. Clin. Psychiat. 2(2):2000;49-54.
16. Gower A.J., Noyer M., Verloes R., Gobert J., Wulfert E. UCB L059, a novel anticonvulsant drug: pharmacological profile in animals. Eur. J. Pharmacol. 222:1992;193-203.
17. Griebel G., Moreau J.-L., Jenck F., Martin J.R., Misslin R. Some critical determinants of the behaviour of rats in the elevated plus-maze. Behav. Processes. 29:1993;37-48.
18. Haller J., Halász J., Makara G.B. Housing conditions and the anxiolytic efficacy of buspirone: the relationship between the main and side effects. Behav. Pharmacol. 11:2000;403-412.
19. Handley S.L., Mithani S. Effects of alpha-adrenoceptor agonists and antagonists in maze-exploration model of "fear"-motivated behaviour. Naunyn-Schmeiderberg's Arch. Pharmacol. 327:1984;1-5.
20. Holmes A., Rodgers R.J. Prior exposure to the elevated plus-maze sensitizes mice to the acute behavioural effects of fluoxetine and phenelzine. Eur. J. Pharmacol. 459:2003;221-230.
21. Klitgaard H. Levetiracetam: the preclinical profile of a new class of anti-epileptic drugs. Epilepsia. 42(Suppl. 4):2001;13-18.
22. Klitgaard H., Matagne A., Gobert J., Wulfert E. Evidence for a unique preclinical profile of levetiracetam in rodent models of seizure and epilepsy. Eur. J. Pharmacol. 353:1998;191-206.
23. Korte S.M., De Boer S.F. A robust animal model of state anxiety: fear potentiated behaviour in the elevated plus-maze. Eur. J. Pharmacol. 463:2003;163-175.
24. Kostowski W., Dyr W., Krzascik P., Jarbe T., Archer T. 5-Hydroxytryptamine 1A receptor agonists in animal models of depression and anxiety. Pharmacol. Toxicol. 71:1992;24-30.
25. Lal H., Prather P.L., Rezazdeh S.M. Anxiogenic behaviour in rats during acute and protracted withdrawal: reversal by buspirone. Alcohol. 8:1991;467-471.
26. Lamberty Y., Gower A.J., Klitgaard H. The new antiepileptic drug levetiracetam normalises chlordiazepoxide withdrawal-induced anxiety in mice. Eur. J. Pharmacol. 439:2002;101-106.
27. Lamberty Y., Falter U., Gower A.J., Klitgaard H. Anxiolytic profile of the anti-epileptic drug levetiracetam in a Vogel conflict test in the rat. Eur. J. Pharmacol. 469:2003;97-102.
28. Lister R.G. The use of the plus-maze to measure anxiety in the mouse. Psychopharmacology. 92:1987;180-185.
29. Loscher W., Hönack D., Bloms-Funke P. The novel antiepileptic drug levetiracetam (ucb L059) induces alterations in GABA metabolism and turnover in discrete areas of rat brain and reduces neuronal activity in substantia nigra pars reticulata. Brain Res. 735:1996;208-216.
30. Margineanu D.G., Klitgaard H. Levetiracetam: mechanisms of action. Levy R.H., Mattson R.H., Meldrum B.S., Perucca E. Antiepileptic Drugs. 5th ed. 2002;Lippincott Williams & Wilkins, Philadelphia.
31. a receptors. Brains Res. Rev. 29:1999;196-217.
32. Montgomery K.C., Monkman J.A. The relation between fear and exploratory behaviour. J. Comp. Physiol. Psychol. 48:1955;132-136.
33. Moser P.C. Evaluation of the elevated plus-maze test using the novel anxiolytic buspirone. Psychopharmacology. 99:1989;48-53.
34. 1A selective ligand and its effect in animal models of anxiety; a comparison with buspirone, 8-OH-DPAT and diazepam. Br. J. Pharmacol. 99:1990;343-349.
35. Noyer M., Gillard M., Matagne A., Hénichart J.-P., Wülfert E. The novel antiepileptic drug levetiracetam appears to act via a specific binding site in CNS membranes. Eur. J. Pharmacol. 286:1995;137-146.
36. Pellow S., File S.E. Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated plus-maze; a novel test of anxiety in the rat. Pharmacol. Biochem. Behav. 24:1986;525-529.
37. Pellow S., Chopin P., File S.E., Briley M. Validation of open: closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J. Neurosci. Methods. 14:1985;149-167.
38. Rigo J.-M., Hans G., Nguyen L., Rocher V., Belachew S., Malgrange B., Leprince P., Moonen G., Selak I., Matagne A., Klitgaard H. The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA- and glycine-gated currents. Br. J. Pharmacol. 136:2002;659-762.
39. Rodgers R.J., Johnson J.T. Factor analysis of spatiotemporal and ethological measures in the murine elevated plus-maze test of anxiety. Pharmacol. Biochem. Behav. 52:1995;297-303.
40. Rodgers R.J., Shepherd J.K. Influence of prior experience on behaviour and response to diazepam in the elevated plus-maze and light/dark tests of anxiety in mice. Psychopharmacology. 113:1993;237-242.
41. Rodgers R.J., Johnson N.J.T., Carr J., Hodgson T.P. Resistance of experimentally-induced changes in murine plus-maze behaviour to altered retest conditions. Behav. Brain Res. 86:1997;71-77.
42. Rodgers R.J., Haller J., Halsz J., Mikics E. "One-trial sensitization" to the anxiolytic-like effects of cannabinoid receptor antagonist SR141716A in the mouse elevated plus-maze. Eur. J. Neurosci. 17:2003;1279-1286.
43. Sayin U., Purali N., Özkan T., Altug A., Büyükdevrim S. Vigabatrin has an anxiolytic effect in the elevated plus-maze test of anxiety. Pharmacol. Biochem. Behav. 43:1992;529-535.
44. Schmitt U., Luddens H., Hiemke C. Anxiolytic-like effects of acute and chronic GABA transporter inhibition in rats. J. Neural Transm. 109:2002;871-880.
45. Singh L., Field M.J., Ferris P., Hunter J.C., Oles R.J., Williams R.G., Woodruff G.N. The anti-epileptic agent gabapentin (Neurontin) possesses anxiolytic-like and antinociceptive actions that are reversed by d-serine. Psychopharmacology. 127:1996;1-9.
46. Shepherd J.K. Preliminary evaluation of an elevated "zero- maze" as an animal model of anxiety in rats. J. Psychopharmacol. 6(A56):1992;223.
47. Treit D., Menard J., Royan C. Anxiogenic stimuli in the elevated plus-maze. Pharmacol. Biochem. Behav. 44:1993;463-469.
48. Zangrossi H. Jr., Leite J.R., Graeff F.G. Anxiolytic effect of carbamazepine in the elevated plus-maze: possible role of adenosine. Psychopharmacology (Berl.). 106:1992;85-89.